This information was published, 2016-04-20 10:27 CEST (GLOBE NEWSWIRE) --
“In line with building out our management team to drive our commercial ambitions, I am delighted Dan is joining at what is an important period in the company’s expansion. Dan’s entire career to date has been spent in market leading companies including Stryker, Zimmer and most recently, Lima Corp. Dan’s experience with Lima’s patient specific implants will add real value to Episurf Medical as we continue to build high impact marketing programs”, says Rosemary Cunningham Thomas, Episurf Medical CEO.
“I am extremely excited to be joining Episurf Medical as the company's technologies start to become clinically accepted and the benefit to patients is being proven. By identifying customer needs and offering our unique solutions to the market, Episurf Medical has unrivalled solutions to help many patients suffering with early knee arthritis. Successfully commercialising its patient specific technology is going enable Episurf Medical to become a valued partner to orthopaedic surgeons and will offer hope to many knee pain sufferers”, says Dan Griffiths.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
rosemary@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
